Evidence map›Paper›PMID 39291006›Full record

ArticleACS medicinal chemistry letters2024

An Automated Purification Workflow Coupled with Material-Sparing High-Throughput

Justin Bellenger, Martin R M Koos, Melissa Avery, Mark Bundesmann, Gregory Ciszewski, Bhagyashree Khunte, Carolyn Leverett, Gregory Ostner, Tim F Ryder, Kathleen A Farley

Abstract read
In one paragraph

Article in ACS medicinal chemistry letters, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Justin BellengerMedicine Design, Pfizer Inc., 445 Eastern Point Rd, Groton, Connecticut 06340, United States.ORCID https://orcid.org/0000-0001-5029-8114
Martin R M KoosMedicine Design, Pfizer Inc., 445 Eastern Point Rd, Groton, Connecticut 06340, United States.ORCID https://orcid.org/0000-0002-7829-4729
Melissa AveryMedicine Design, Pfizer Inc., 445 Eastern Point Rd, Groton, Connecticut 06340, United States.
Mark BundesmannMedicine Design, Pfizer Inc., 445 Eastern Point Rd, Groton, Connecticut 06340, United States.
Gregory CiszewskiMedicine Design, Pfizer Inc., 445 Eastern Point Rd, Groton, Connecticut 06340, United States.
Bhagyashree KhunteMedicine Design, Pfizer Inc., 445 Eastern Point Rd, Groton, Connecticut 06340, United States.
Carolyn LeverettMedicine Design, Pfizer Inc., 445 Eastern Point Rd, Groton, Connecticut 06340, United States.
Gregory OstnerMedicine Design, Pfizer Inc., 445 Eastern Point Rd, Groton, Connecticut 06340, United States.
Tim F RyderMedicine Design, Pfizer Inc., 445 Eastern Point Rd, Groton, Connecticut 06340, United States.
Kathleen A FarleyMedicine Design, Pfizer Inc., 445 Eastern Point Rd, Groton, Connecticut 06340, United States.ORCID https://orcid.org/0000-0001-8935-6852

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In medicinal chemistry, purification and characterization of organic compounds is an ever-growing challenge, with an increasing number of compounds being synthesized at a decreased scale of preparation. In response to this trend, we developed a parallel medicinal chemistry (PMC)-tailored platform, coupling automated purification to mass spectrometry (MS) and nuclear magnetic resonance spectroscopy (NMR) on a range of synthetic scales (∼3.0-75.0 μmol). Here, the generation and acquisition of 1.7 mm NMR samples is fully integrated into a high-throughput automated workflow, processing 36 000 compounds yearly. Utilizing dead volume, which is inaccessible in conventional liquid handling, NMR samples are generated on as little as 10 μg without consuming material prioritized for biological assays. As miniaturized PMC synthesis becomes the industry standard, we can now obtain quality NMR spectra from limited material. Paired with automated structure verification, this platform has the potential to allow NMR to become as important for high-throughput analysis as ultrahigh performance liquid chromatography (UPLC)-MS.

Identifiers

PMID39291006
PMCPMC11403749

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.